[Is the use of @entity632 ( @entity632 ) limited by its XXXX ?].

@entity632 @entity1 @entity712 @entity8253 @entity4349 @entity5 @entity1370
@entity632 ( @entity632 ), one of the most active cytotoxic antineoplastic agents, can cause @entity712 . This side effect is dose-dependent, the frequency of @entity712 being 3% at a cumulative @entity632 dose of 400 mg/m2 and 18% at 700 mg/m2. It is assumed that @entity632 , or other @entity4349 derivatives, are still active when the @entity1370 level is reached. In this retrospective study of 171 @entity1 with various metastatic @entity5 , the total dose of @entity632 given to the @entity1 and the reasons for withholding the treatment have been analyzed. Overall, among the 171 @entity1 treated by @entity632 -containing combination chemotherapy, 54 objective remissions (31%) were observed. Remissions were more frequent in untreated @entity1 (52%) than in previously treated @entity1 (20%). In 36 of 54 @entity1 the disease progressed before the cumulative @entity1370 level was reached. @entity632 could be discontinued in only 18 @entity1 still in remission. 8 of 171 @entity1 received more than 450 mg/m2 @entity632 without @entity1370 side effects being observed. Among the 171 @entity1 , @entity1370 probably related to @entity8253 developed in 5 cases (3%), in all cases at a level below 450 mg/m2. These results suggest that in most cases @entity632 becomes inactive before the dose-limiting cumulative @entity1370 level is reached.
